期刊文献+

乳腺癌分子分型特征与数字乳腺断层摄影征象相关性的研究进展 被引量:8

暂未订购
导出
摘要 乳腺癌一直是女性癌症相关死亡事件的首要因素。分子分型为乳腺癌患者的个性化精确治疗策略提供了关键证据,并进一步提高了患者生存率。乳腺癌最终的分子病理往往需要术前穿刺活检或手术标本的免疫组化分析的支持,但这一过程有创且采样不足,分析不完整,不能很好地反映癌巢整体信息。与其他常规影像学检查方法相比,数字乳腺断层摄影(digital breast tomosynthesis,DBT)作为一种无创影像学检查工具,在揭示乳腺癌的结构特征、分子分型、鉴别诊断和临床分期评估等方面发挥着更加全面有效的作用。本文综述了乳腺癌各分子亚型的病理特征、临床治疗现状及典型DBT影像学征象,旨在为其早期准确诊断、个性化治疗、合理监测生物学行为、评估疗效及预后提供更客观的证据。
出处 《江苏大学学报(医学版)》 CAS 2023年第1期79-83,共5页 Journal of Jiangsu University:Medicine Edition
基金 江苏省研究生实践创新计划(SJCX20_1436) 镇江市社会发展指导性科技计划项目(FZ2021055)。
  • 相关文献

参考文献3

二级参考文献58

  • 1Perou CM, Scrlie T, Eisen MB, et al. Molecular portraits of human breast turnouts[J]. Nature, 2000, 406(6797):747- 752.
  • 2Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol, 2009, 20(8): 1319-1329.
  • 3Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer[J]. N Engl J Med, 1976, 294(8):405-410.
  • 4Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from National Surgical Adjuvant Breast and Bowel Project B-15 [J]. J Clin Oncol, 1990, 8 (9): 1483-1496.
  • 5Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 365 (9472):1687- 1717.
  • 6Nowak AK, Ferguson T, Wilcken N, et al. A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer (EBC)[J]. J Clin Oncol, 2007, ASCO Annual Meeting Proceedings Part I , 25: 18S (June 20 Suppl): 545.
  • 7Galea MH, Blarney RW, Elston CE, et al. The Nottingham prognostic index in primary breast cancer[J]. Breast Cancer Res Treat, 1992, 22(3):207-219.
  • 8Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival[J]. Clin Cancer Res, 2007,13(15 Pt1): 4415-4421.
  • 9Ellis M J, Coope A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1 and/or ErbB-2-positive primary breast cancer: evidence from a phrase Ⅲ randomized trail [J]. J Clin Oncol, 2001, 19(18):3808-3816.
  • 10Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8): 2329-2334.

共引文献3611

同被引文献97

引证文献8

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部